Andreas G. Grill
President & CEO / Director
Mr. Grill is the former Executive Director for Pharmaceutical Research & Development at Forest Research Institute,
a subsidiary of Forest Laboratories, Inc. (now Allergan). Mr. Grill has extensive experience and knowledge in
pharmaceutical research and development including all aspects of biopharmaceutics, formulation development,
analytical development, preformulation, bioanalytical and drug metabolism as well as significant experience in
drug discovery, regulatory affairs and drug licensing with over twenty three years of experience in the
pharmaceutical / biotechnology industry. Founder and President of Advanced Pharmaceutical Strategies, LLC, a consulting firm for drug product development working with multiple cancer therapeutic development companies. Successful drug development achievements include a wide range of indications and a broad range of pharmaceutical dosage forms. Mr. Grill is responsible for contributing to a significant number of pharmaceutical drug product approvals within the United States and worldwide. The products within Mr. Grills impressive portfolio include Lexapro®, Namenda®, Campral®, Combunox®, Bystolic®, Savella®, Namenda XR®, Teflaro™, Daliresp™, Linzess™, Namzaric™, and Vraylar™. Continuous support of the scientific community with more than thirty presentations, abstracts and publications as well as listed inventor on multiple pharmaceutical relevant patents. Advisory Board Member for Stony Brook University - Institute of Chemical Biology & Drug Discovery, Advisor for the BioStrategy Sessions at SUNY Stony Brook – Center of Biotechnology, Member of the Bioscience Advisory Board for SUNY Farmingdale as well as a member of the Board of Directors for the Farmingdale College Foundation. Mr. Grill holds a Bachelor of Science in Biochemistry from the State University of New York at Stony Brook with graduate studies in Pharmacology/Toxicology at Saint John’s University and a Master of Business Administration from Dowling College.
Mr. Backenroth serves as the Chief Financial Officer and Vice President of Business Development for Ohr Pharmaceutical, Inc. (NasdaqCM:OHRP). Mr. Backenroth has executive experience in advising and financing biotechnology companies. He previously worked as an Investment Banker with The Benchmark Company LLC, an Investment Banking firm specializing in micro-cap biotechnology transactions. While at Benchmark, Sam helped fund numerous small biotechnology companies raise equity growth capital through a variety of structures. Mr. Backenroth also acted as an advisor to multiple public and private biotechnology and pharmaceutical companies in assisting with business development activities, joint ventures, licensing, strategic partnerships, and mergers & acquisitions. He graduated with honors from Touro College with a Bachelor's degree in finance.
Peter is an experienced life-science industry consultant and executive-in-residence with Pappas Capital,
where he leads the firm’s initiatives in translational medicine and is the Program Manager for the Wake
Forest Technology Development Program. Peter has over thirty-five years’ experience in the pharmaceutical
and biotech industry, spanning all areas of the business from sales representative to country-level general
manager and CEO and companies ranging from multinationals like Abbott and Glaxo to start-up biotechs.
At Glaxo Wellcome in the mid-1990s he led the global introduction of combination HIV therapy while keying industry leadership on global treatment access. Peter currently serves on the Oversight Committee for the University of Miami Wallace H. Coulter Center for Translational Research and as an Executive in Residence at Cold Spring Harbor Laboratories and the Center for Biotechnology at Stony Brook University. He is a member of the Long Island Bioscience Hub External Review Board and the Long Island Biomentor Initiative, a past member of the BIO board and chairman of the North Carolina Biosciences Organization, and director of Memory Pharmaceuticals from 2004 until its sale to Roche in 2009. He has lived and worked in the US, Greece and the Middle East, Puerto Rico, New Zealand, and London, and currently lives with his family in New York. He has a BA and an MBA from Indiana University.
Thomas M. Riedhammer, Ph.D.
Dr. Riedhammer most recently served as Chairman of Sirion Therapeutics Inc, a position he held since 2007. Prior
to that, Dr. Riedhammer served as Chief Operating Officer of Presby Corp., a medical device company engaged in
the research and development of treatments for eye disorders. Prior to Presby Corp., Dr. Riedhammer served as
President and Senior Vice President of Worldwide Pharmaceuticals at Bausch and Lomb from 1994 to 2000. He
also held various other positions at Bausch and Lomb including: Senior Vice President, and Chief Technical Officer
from 1998 to 2000, Senior Vice President and President for Worldwide Pharmaceutical, Surgical, and Hearing Care Products from 1994 to 1998, and Vice President from 1993 to 1994. He was a corporate Vice President of Paco Pharmaceuticals and President of Paco Research Corp from 1984 to 1991. Dr. Riedhammer began his career at Bausch & Lomb as a Research Chemist and was its Director, Lens Care Products R&D. He has served as Chairman and Director of Prevent Blindness Florida, Director of Prevent Blindness America, Sjogren's Syndrome Foundation as secretary and Junior Achievement International. Dr. Riedhammer holds a B.A. in Chemistry and a Ph.D. in Electrochemistry from State University of New York at Buffalo.
Mr. Whiteley has over 30 years experience of strategic management and marketing of leading edge technologies
to the Life Science industry. Most recently Andrew was Chief Operating Officer at Enzo Life Sciences, the head of
the product division of Enzo Biochem Inc. (NYSE: ENZ), and was previously CEO of Vitra Bioscience, the developer
of CellPlex assays for drug candidate profiling. Andrew was also Chairman and CEO of InforMax Inc (NASDAQ:
INMX), the leading supplier of Bioinformatics analysis tools. He was responsible for the restructuring and sale of
the company to Invitrogen.
Prior to Vitra Bioscience, Andrew had an extensive career at Amersham Biosciences initially in Europe including Business Manager for Central Europe and Head of Strategic Marketing for Cell Biology and Molecular Biology products. Andrew moved to the United States in 1996 to become Site Director for Amersham’s Cleveland site, where he oversaw the successful transition of the Sequencing business to New Jersey. He then moved to the West Coast as VP of Sequencing at Molecular Dynamics. Andrew was responsible for the launch and first year sales of the MegaBACE DNA sequencer. Andrew became VP of Bioinformatics to build this new business area and during this time served as external board director to InforMax Inc, Cimarron Software and Imaging Research Inc. Andrew graduated from Nottingham University in the UK with an honors degree in Biochemistry and Chemistry.
Mr. Winick is the Managing Director at Topspin Partners. He had been with Honeywell (and the Ademco division of
Pittway Corp., before its acquisition by Honeywell in 2000) for over 21 years as CTO of the security business, as well
as founder and president of its wireless communications services business. Mr. Winick received a B.S. in Economics
from the Wharton School of the University of Pennsylvania in 1971 and a B.S. in Electrical Engineering in 1972, also from Pennsylvania. He received his J.D. from Georgetown University Law Center and is a registered Patent Attorney.